vTv Therapeutics Inc. (NASDAQ: VTVT) is a clinical-stage biopharmaceutical company focused on the discovery and development of orally available small molecule drugs for the treatment of metabolic and neurodegenerative disorders. Since its inception in 2004 and its headquarters in High Point, North Carolina, vTv has pursued a two-pronged strategy of in-house drug discovery and strategic partnerships to advance its pipeline efficiently. The company’s proprietary technology platform is designed to identify and optimize novel compounds that can modulate key biological targets implicated in diseases such as diabetes, Alzheimer’s, and Parkinson’s.
Among vTv’s lead assets is TTP399, a liver-selective glucokinase activator under investigation as an adjunct therapy for type 1 diabetes. This candidate has demonstrated the potential to improve glycemic control while reducing risks of hypoglycemia in early clinical studies. In addition, the company is advancing TTP273, a novel oral agonist of the GLP-1 receptor for type 2 diabetes, and TTP850, a small molecule inhibitor of the calcitonin gene–related peptide (CGRP) receptor for the prevention of migraine. Through its disciplined development approach, vTv aims to de-risk key programs by generating robust proof-of-concept data before seeking broader collaborations or licensing agreements.
vTv Therapeutics operates primarily in the United States but collaborates with international research organizations and contract research organizations (CROs) to support global clinical trials. The company has entered into strategic partnerships with major pharmaceutical firms to leverage external expertise and expand the reach of its pipeline candidates. These collaborations have enabled vTv to optimize its resources, accelerate timelines, and maintain a lean organizational structure while retaining rights to its core technologies.
Leadership at vTv is spearheaded by Michael L. Ray, Chief Executive Officer and Director, who brings over 25 years of experience in biopharmaceutical development and corporate strategy. The management team includes seasoned experts in clinical operations, regulatory affairs, and business development, many of whom have held senior roles at global life sciences companies. Together, they guide vTv’s mission to deliver innovative, orally administered therapies that address unmet medical needs in diabetes and neurodegenerative diseases.
AI Generated. May Contain Errors.
Free VTVT Stock Alerts